Centessa IPO Presentation Deck

Our Pipeline: Other Programs PegaOne Janp¹H CAPELLA BION Orexia Therapeutics LockBody PearRiver PROGRAM Imgatuzumab STAT3/5 Degrader CB5001 CBS004 OX2R Agonists.com Oral/Intranasal CD47 LB1 CD3 LB2 Exon20 C7975 NextGen MoA Anti-EGFR mAb Dual-STAT3/5 Degrader Anti-LIGHT mAb Anti-BDCA-2 mAb WODOX2R Agonist CD47 Bi-specific CD3 Bi-specific EGFR-EX20 Inhibitor EGFR-C797S Inhibitor EGFR Inhibitor DEEP EXPERTISE Dr. Steffen Heeger Physician deeply involved in the development of Imclone's anti- EGFR mAb cetuximab Dr. Patrick Gunning 15+ years experience in STAT structural understanding, deep biochemistry knowledge Dr. Steve Holmes 30+ years experience in development of mAb therapeutics (Domantis, GSK) Dr. Deborah Hartman Deep experience in orexin drug development (Takeda) Dr. John Finlay 20+ years experience in biopharmaceutical discovery and development (Pfizer, Wyeth) Dr. Roman Thomas Has worked on the genetics and biology of lung cancer for more than 15 years KEY ATTRIBUTES Next generation anti-EGFR mAb treatment for CSCC with enhanced Fc-receptor based immune effector activity with potential synergy with immunotherapies Covalent binding non-PROTAC small molecule degrader of STAT3 and STAT5 for hematological malignancies High potency mAbs designed to treat chronic progressive inflammatory disease Deep structure resolution-based design of orexin receptor agonists for oral or intranasal delivery Efficient targeting and local-only release of highly active immune modulating anti-CD47 and anti-CD3 therapeutics Structural insights into Ex20 mutations Novel mode of action to potentially address Osimertinib resistance mutations (C7975) CENTESSA 29

View entire presentation